"Invisible burials" and fragmentation practices in Iron Age Europe:Excavations at the Monte Bernorio Necropolis (Northern Spain)

The scarcity of burial remains in large parts of Iron Age Europe, particularly in the Atlantic regions, has often led scholars to discuss the apparent “invisibility” of graves. This paper presents the results from several excavation campaigns at Monte Bernorio, one of the most important sites of the 1st millennium b.c. on the Iberian Peninsula. The fieldwork and post-excavation work carried out in the area of the necropolis have identified numerous burial pits, with complex ritual activities characterized by fragmentation and the practice of the pars pro toto. In addition, evidence for later rituals in some of the graves can be linked to ancestor worship. The results provide important insights into funerary practices in Late Iron Age Europe, leading us to rethink the very meaning of cemeteries in the study area and beyond.- Burial Traditions in Iron Age Europe - The Monte Bernorio Archaeological Zone - The 2007–2008 Necropolis Excavations - The 2015–2016 Necropolis Excavations - Post-Excavation Work and Interpretation: The Faunal and Human Remains - Structure and Chronology of Monte Bernorio Area 7 - Destruction of the Body, Commemoration in the Absence of a Corpse, and Visibility of the Mortuary Rite

Pargyline-induced increases in sensitivity to the effects of drugs on operant behavior in pigeons

Pigeons responded under a multiple fixedinterval 5-min, 30-response fixed-ratio schedule of food reinforcement. Acute pargyline doses between 10.0 and 50.0 mg/kg (i.m.), given immediately prior to the session, decreased responding. Daily administration of 50 mg/kg pargyline (24 mg/kg, every 12 h) initially decreased responding. Tolerance developed so that after 4 days of daily pargyline, responding had returned to control values. Chronic pargyline resulted in an enhanced sensitivity to the effects of d -amphetamine, ephedrine, tyramine, and morphine on schedule-controlled responding. Both d -amphetamine and pentobarbital increased fixed-interval responding at relatively low doses, while higher doses decreased responding. Daily pargyline resulted in an increased sensitivity to both the increases and decreases in response rates produced by d -amphetamine. In contrast, sensitivity to pentobarbital was not changed after daily pargyline. Ephedrine, tyramine, and morphine only decreased fixed-interval responding. Chronic pargyline resulted in an increased sensitivity to the response-rate decreasing effects of ephedrine, tyramine, and morphine. In addition to the increased sensitivity of fixed-interval responding to the effects of tyramine, the dose-effect curve for fixed-ratio responding was also a shifted to the left. Daily pargyline did not result in changes in sensitivity of fixedratio responding to the effects of the other drugs tested.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46399/1/213_2004_Article_BF00426607.pd

Diagnosi e trattamento delle rotture dei corpi cavernosi: cosa è cambiato?

Gli Autori espongono un aggiornamento sulla base della revisione della letteratura delle modalità di approccio diagnostico e di trattamento alla rottura dei corpi cavernos

Indole alkaloids XVII: Five dihydroindole alkaloids from Aspidosperma verbascifolium

A study of Aspidosperma verbascifolium has led to the isolation of four known dihydroindole alkaloids: kopsanone [I], kopsanol [II], 3'‐epikopsanol [III], 10‐oxo‐3'‐epikopsanol [IV] and a new natural product: Nα‐formylkopsanol [VII]. Copyright © 1969 Wiley‐VCH Verlag GmbH & Co. KGaA, WeinheimSCOPUS: ar.jinfo:eu-repo/semantics/publishe

The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: a prospective non blinded study utilizing flower pollen extracts versus bioflavonoids

Introduction: Chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) represents a challenge for the urologist, since the therapeutic efficacy does not always result in a satisfactory quality of life for the patients. Often the side effects of the medications used (anti-inflammatories, antibiotics, alpha blockers) far outweighs the benefits gained with their admission. The choice of nutraceutical medications is preferred for their effectiveness, that has been accepted and proven by the scientific community, and for the low incidence of side effects. The objective of this study to compare the therapeutic efficacy of the flower pollen extracts (Deprox ® ) versus Bioflavonoids in terms of reduction of symptoms, and in the average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and to evaluate the quality of life improvement of the patients affected by CP/CPPS. Methods: Among the 68 patients presented with prostatic symptoms to the Hospital “Umberto I” in Rome, Italy between March 2016 and June 2016, 54 patients met the clinical diagnosis of CP/CPPS (class IIIa or IIIb according to the NIH classification). The patients were assigned to either treatment with Deprox ® or quercetin based on a randomization scheme previously determined.The NIH- CPSI, IPSS, QoL questionnaires were administered. Every patient underwent bacterial cultures and trans-rectal ultrasound. Results: There was a statistically significant improvement of the NIH-CPSI score and QoL in the Deprox ® group (p = < 0.0001 and p = 0.003 respectively). The average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was statistically significant (p = 0.0019). In the absence of efficacy of the “conventional” medications, which also carries significant side effects, the dietary supplements may represent a valid alternative. Conclusions: DEPROX ® has demonstrated a significant improvement of the symptoms and quality of life of patients diagnosed with by CP/CPPS. Furthermore, there was a statistical difference in the average waiting time of the variation of the NIH-CPSI) score without side effects as compared to the bioflavonoids complex with quercetin